# SAFETY DATA SHEET

## Imipenem / Cilastatin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.0</td>
<td>03/20/2023</td>
<td>15845-00026</td>
<td>08/23/2022</td>
<td>11/05/2014</td>
</tr>
</tbody>
</table>

## SECTION 1. IDENTIFICATION

**Product name**: Imipenem / Cilastatin Formulation

**Manufacturer or supplier’s details**

- **Company name of supplier**: Merck & Co., Inc
- **Address**: 126 E. Lincoln Avenue, Rahway, New Jersey U.S.A. 07065
- **Telephone**: 908-740-4000
- **Emergency telephone**: 1-908-423-6000
- **E-mail address**: EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**

- **Recommended use**: Pharmaceutical
- **Restrictions on use**: Not applicable

## SECTION 2. HAZARDS IDENTIFICATION

### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

- **Combustible dust**
- **Eye irritation**: Category 2A
- **Respiratory sensitization**: Category 1
- **Reproductive toxicity**: Category 2

### GHS label elements

- **Hazard pictograms**: ![Image]
- **Signal Word**: Danger
- **Hazard Statements**: If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
  H319 Causes serious eye irritation.
  H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
  H361d Suspected of damaging the unborn child.
- **Precautionary Statements**: **Prevention:**
  P201 Obtain special instructions before use.
  P202 Do not handle until all safety precautions have been read and understood.
  P261 Avoid breathing dust.
  P264 Wash skin thoroughly after handling.
  P280 Wear protective gloves, protective clothing, eye protection.
and face protection.
P285 In case of inadequate ventilation wear respiratory protection.

Response:
P304 + P341 IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical attention.
P337 + P313 If eye irritation persists: Get medical attention.
P342 + P311 If experiencing respiratory symptoms: Call a doctor.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1</td>
<td>50.1</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>49</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
## SAFETY DATA SHEET

**Imipenem / Cilastatin Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.0</td>
<td>03/20/2023</td>
<td>15845-00026</td>
<td>08/23/2022</td>
<td>11/05/2014</td>
</tr>
</tbody>
</table>

**If swallowed**
- If swallowed, **DO NOT** induce vomiting.
- Get medical attention.
- Rinse mouth thoroughly with water.

**Most important symptoms and effects, both acute and delayed**
- Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
- Contact with dust can cause mechanical irritation or drying of the skin.
- Causes serious eye irritation.
- May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Suspected of damaging the unborn child.

**Protection of first-aiders**
- First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**Notes to physician**
- Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

**Suitable extinguishing media**
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

**Unsuitable extinguishing media**
- None known.

**Specific hazards during fire fighting**
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

**Hazardous combustion products**
- Carbon oxides

**Specific extinguishing methods**
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

**Special protective equipment for fire-fighters**
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up:
- Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air.
- Add excess liquid to allow the material to enter into solution.
- Soak up with inert absorbent material.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Avoid breathing dust.
- Do not swallow.
- Do not get in eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Component Description</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>iner or nuisance dust</td>
<td></td>
<td>50 Million particles per cubic foot</td>
<td>TWA (total dust)</td>
<td>OSHA Z-3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 mg/m³</td>
<td>TWA (total dust)</td>
<td>OSHA Z-3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 mg/m³</td>
<td>TWA (respirable fraction)</td>
<td>OSHA Z-3</td>
</tr>
<tr>
<td>Dust, nuisance dust and particulates</td>
<td></td>
<td>10 mg/m³</td>
<td>TWA (respirable dust fraction)</td>
<td>CAL PEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 mg/m³</td>
<td>TWA (respirable dust fraction)</td>
<td>CAL PEL</td>
</tr>
</tbody>
</table>

Components

<table>
<thead>
<tr>
<th>Component</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td>81129-83-1</td>
<td>TWA</td>
<td>5 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td>Imipenem</td>
<td>74431-23-5</td>
<td>TWA</td>
<td>1000 ug/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: RSEN

Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection

General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide...
hand protection
Material: Chemical-resistant gloves

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder
Color: white
Odor: sulfurous
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): Not applicable
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapor pressure: Not applicable
Relative vapor density: Not applicable
Relative density: No data available
Density: 1 g/cm³
Solubility(ies)
   Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Autoignition temperature: No data available
Decomposition temperature: No data available
Viscosity
   Viscosity, dynamic: No data available
   Viscosity, kinematic: Not applicable
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions
   May form explosive dust-air mixture during processing, handling or other means.
   Can react with strong oxidizing agents.
Conditions to avoid
   Heat, flames and sparks.
   Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
   Inhalation
   Skin contact
   Ingestion
   Eye contact
Acute toxicity
   Not classified based on available information.
SAFETY DATA SHEET

Imipenem / Cilastatin Formulation

Components:

Cilastatin:
- Acute oral toxicity: LD50 (Rat): 8,000 mg/kg
  LD50 (Mouse): 8,000 mg/kg

Imipenem:
- Acute oral toxicity: LD50 (Mouse): 10,000 mg/kg
- Acute toxicity (other routes of administration):
  LD50 (Rat): > 2,000 mg/kg
  Application Route: Intravenous
  LD50 (Mouse): 1,500 mg/kg
  Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Components:

Cilastatin:
- Species: Rabbit
  Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

Cilastatin:
- Species: Rabbit
  Result: Moderate eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cilastatin:
- Routes of exposure: Skin contact
  Remarks: No data available
- Routes of exposure: Inhalation
  Remarks: No data available

Imipenem:
- Remarks: May cause sensitization of susceptible persons by inhalation
Routesto of exposure:

Skin contact

Remarks:
Not classified due to lack of data.

Germ cell mutagenicity
Not classified based on available information.

Components:

Cilastatin:
Genotoxicity in vitro:
Test Type: Microbial mutagenesis assay (Ames test)
Result: negative

Imipenem:
Genotoxicity in vitro:
Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: reverse mutation assay
Result: negative

Test Type: unscheduled DNA synthesis assay
Result: negative

Test Type: Chromosomal aberration
Result: negative

Test Type: sister chromatid exchange assay
Result: negative

Genotoxicity in vivo:
Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intravenous
Result: negative

Carcinogenicity
Not classified based on available information.

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

Cilastatin:
SAFETY DATA SHEET

Imipenem / Cilastatin Formulation

Effects on fertility

Test Type: Fertility/early embryonic development
Application Route: Intravenous
Fertility: LOAEL: 1,000
Symptoms: No adverse effects.
Result: No effects on fertility and early embryonic development were detected.

Imipenem:

Effects on fertility

Species: Rat, male and female
Application Route: Intravenous
Fertility: LOAEL: 80 mg/kg body weight
Symptoms: No adverse effects., Reduced fetal weight.
Result: No effects on fertility and early embryonic development were detected.

Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Subcutaneous
Fertility: LOAEL: 320 mg/kg body weight
Symptoms: No adverse effects., Reduced fetal weight.
Result: No effects on fertility and early embryonic development were detected.

Effects on fetal development

Test Type: Development
Species: Monkey
Application Route: Intravenous
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development
Species: Rabbit
Application Route: Intravenous
Developmental Toxicity: NOAEL: 60 mg/kg body weight
Result: No teratogenic effects.

Test Type: Development
Species: Rat
Application Route: Intravenous
Developmental Toxicity: NOAEL: 60 mg/kg body weight
Result: No teratogenic effects.

Reproductive toxicity - Assessment

Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Not classified based on available information.
Repeated dose toxicity

**Components:**

**Cilastatin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt;= 500 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>&gt;= 500 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>5 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Imipenem:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>60 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Monkey</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>120 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>180 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>150 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Kidney</td>
</tr>
</tbody>
</table>

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

**Components:**

**Imipenem:**

<table>
<thead>
<tr>
<th>Inhalation</th>
<th>Symptoms: Nausea, Vomiting, Diarrhea, Fever, hypotension, Dizziness, Drowsiness, Convulsions, pruritis, Rash</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remarks</td>
<td>May cause sensitization of susceptible persons by inhalation of aerosol or dust.</td>
</tr>
</tbody>
</table>
Ecotoxicity

Components:

Cilastatin:

Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 111 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 99 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:

- EC50 (Anabaena flos-aquae): > 99 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
- EC50 (Pseudokirchneriella subcapitata (green algae)): > 99 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
- NOEC (Anabaena flos-aquae): 99 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 99 mg/l
  Exposure time: 72 h
  Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity):

EC10 (Pimephales promelas (fathead minnow)): > 9.9 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):

EC10 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms:

EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Imipenem:

Toxicity to daphnia and other aquatic invertebrates:

EC50 (Daphnia magna (Water flea)): > 78 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants:

EC50 (Anabaena flos-aquae (cyanobacterium)): 0.0046 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
##SAFETY DATA SHEET

###Imipenem / Cilastatin Formulation

**Version 11.0**  
Revision Date: 03/20/2023  
SDS Number: 15845-00026  
Date of last issue: 08/23/2022  
Date of first issue: 11/05/2014

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Result</th>
<th>Exposure Time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NOEC (Anabaena flos-aquae (cyanobacterium))</strong></td>
<td>0.002 mg/l</td>
<td>72 h</td>
<td>OECD Test Guideline 201</td>
</tr>
<tr>
<td><strong>EC50 (Pseudokirchneriella subcapitata (green algae))</strong></td>
<td>&gt; 74 mg/l</td>
<td>72 h</td>
<td>OECD Test Guideline 201</td>
</tr>
<tr>
<td><strong>NOEC (Pseudokirchneriella subcapitata (green algae))</strong></td>
<td>74 mg/l</td>
<td>72 h</td>
<td>OECD Test Guideline 201</td>
</tr>
<tr>
<td><strong>Toxicity to fish (Chronic toxicity)</strong></td>
<td>NOEC (Pimephales promelas (fathead minnow))</td>
<td>9.4 mg/l</td>
<td>OECD Test Guideline 210</td>
</tr>
<tr>
<td><strong>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</strong></td>
<td>NOEC (Daphnia magna (Water flea))</td>
<td>11 mg/l</td>
<td>OECD Test Guideline 211</td>
</tr>
<tr>
<td><strong>Toxicity to microorganisms</strong></td>
<td>EC50: &gt; 1,000 mg/l</td>
<td>3 h</td>
<td>OECD Test Guideline 209</td>
</tr>
</tbody>
</table>

###Persistence and degradability

####Components:

<table>
<thead>
<tr>
<th>Component</th>
<th>Biodegradability</th>
<th>Result</th>
<th>Exposure Time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biodegradability</td>
<td></td>
<td>Not readily biodegradable.</td>
<td>27 %</td>
<td>OECD Test Guideline 301B</td>
</tr>
<tr>
<td>Exposure time</td>
<td></td>
<td>28 d</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component</th>
<th>Biodegradability</th>
<th>Result</th>
<th>Exposure Time</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imipenem</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biodegradability</td>
<td></td>
<td>Not readily biodegradable.</td>
<td>29 %</td>
<td>OECD Test Guideline 301B</td>
</tr>
<tr>
<td>Exposure time</td>
<td></td>
<td>28 d</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

###Bioaccumulative potential

####Components:

<table>
<thead>
<tr>
<th>Component</th>
<th>Partition coefficient: n-octanol/water</th>
<th>log Pow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilastatin</td>
<td></td>
<td>-3.53</td>
</tr>
<tr>
<td>Imipenem</td>
<td></td>
<td>&lt; -1</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Imipenem / Cilastatin Formulation

Mobility in soil

Components:

Cilastatin:

Distribution among environmental compartments: log Koc: 2.3

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues: Dispose of in accordance with local regulations. Do not dispose of waste into sewer.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class: 9
Packing group: III
Labels: 9

IATA-DGR

UN/ID No.: UN 3077
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Imipenem)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 956
Packing instruction (passenger aircraft): 956
Environmentally hazardous: yes

IMDG-Code

UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Imipenem)
Class: 9
Packing group: III
Labels: 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
UN/ID/NA number : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Imipenem)
Class : 9
Packing group : III
Labels : CLASS 9
ERG Code : 171
Marine pollutant : yes (Imipenem)
Remarks : Above applies only to containers over 119 gallons or 450 liters.
Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust
Respiratory or skin sensitization
Reproductive toxicity
Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know
Cilastatin : 81129-83-1
Imipenem : 74431-23-5

The ingredients of this product are reported in the following inventories:
Imipenem / Cilastatin Formulation

SAFETY DATA SHEET

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

Flammability
Health 1 2 0
Instability

HMIS® IV:

HEALTH*

FLAMMABILITY 3

PHYSICAL HAZARD 0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

CAL PEL : California permissible exposure limits for chemical contaminants (Title 8, Article 107)
OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
CAL PEL / PEL : Permissible exposure limit
OSHA Z-3 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemi-
SAFETY DATA SHEET

Imipenem / Cilastatin Formulation

Version 11.0  Revision Date: 03/20/2023  SDS Number: 15845-00026  Date of last issue: 08/23/2022

Revision Date: 03/20/2023

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8